Research and Markets: Gram-Positive Bacterial Infections Global Clinical ...
Our clinical trial report, Gram-Positive Bacterial Infections Global Clinical Trials Review, H2, 2014" provides data on the Gram-Positive Bacterial Infections clinical trial scenario. This report provides elemental information and data relating to the ...
Stockhouse - Thu, 18 Dec 2014 05:41



FDA approvals boost 2 Mass. biotech firms
The current flagship Cubist drug, Cubicin, generates more than $1 billion a year in revenue worldwide targeting infections from Gram-positive bacteria. Zerbaxa has the potential to become as big a seller, according to projections from Cubist and ...
Boston Globe - Fri, 19 Dec 2014 14:59

FDA Approves Second Cubist Antibiotic Of 2014
Forbes - Fri, 19 Dec 2014 15:26

Cubist Pharmaceuticals: An Extraordinary Arbitrage Opportunity
Seeking Alpha - Wed, 17 Dec 2014 08:30

RI hospital find bacterial infections differ based on geography, healthcare ...
... thrive in warm and moist environments, compared to another group of bacteria referred to as Gram-positive bacteria. The study also found that the proportion of a country's GDP spent on health care impacted the type of bacteria causing such infections.
EurekAlert (press release) - Thu, 18 Dec 2014 11:07

XYDALBA™ (dalbavancin) Receives CHMP Positive Opinion for the Treatment ...
XYDALBA is marketed in the United States as DALVANCE® (dalbavancin) for injection. DALVANCE® is indicated for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI) caused by Susceptible Gram-positive bacteria, ...
PR Newswire (press release) - Fri, 19 Dec 2014 13:11

CHMP Backs Dalbavancin (Xydalba) for Acute Skin Infections
Medscape - Fri, 19 Dec 2014 12:03

Durata Therapeutics (DRTX) Receives Positive CHMP Opinion on Xydalba as ...
StreetInsider.com (subscription) - Fri, 19 Dec 2014 04:56



Experimental Drug Shows Dramatic Improvement Against Bacterial Infection in ...
In this study, the research team sought to determine if a possible alternative to traditional antibiotics known as “eCAPs” (engineered cationic antimicrobial peptides), are indeed effective in treating both gram-positive and negative bacteria as well ...
Cystic Fibrosis News Today - Wed, 17 Dec 2014 11:30



FDA Approves Pathogen Reduction System to Treat Platelets
Examples of some of the pathogens that may be reduced using the Intercept Blood System include HIV, hepatitis B and C viruses, West Nile virus and Gram-negative and Gram-positive bacteria. The Intercept process also reduces the number of T cells (a ...
Infection Control Today - Fri, 19 Dec 2014 06:15

Here Is Why Cerus Corporation (CERS) Stock Is Soaring
Bidness ETC - Thu, 18 Dec 2014 02:52

Health Care Sector Update for 12/17/2014: CERS,ASPX,POZN
Nasdaq - Wed, 17 Dec 2014 10:33

Cerus Corp (CERS) Confirms FDA Approval of INTERCEPT Blood System for ...
StreetInsider.com (subscription) - Tue, 16 Dec 2014 14:30

Bloodstream infections differ based on distance from the equator, health care ...
... compared to another group of bacteria referred to as Gram-positive bacteria. The study also found that the proportion of a country's GDP spent on health care impacted the type of bacteria causing such infections. The study was published in the ...
News-Medical.net - Fri, 19 Dec 2014 01:00



New treatment effectively inhibited bacterial growth
Montelaro and colleagues tested the efficacy of engineered cationic antimicrobial peptides, or eCAPs, which were synthesized in the laboratory and have shown broad activity in vitro against both gram-negative and gram-positive pathogens, including ...
Healio - Mon, 15 Dec 2014 13:22


1  2  3  4  5  6  7  8    ->


We do not evaluate or guarantee the accuracy of any content in this site. Click here for the full disclaimer.

Last update: September 2014